Document › Details

Adaptimmune Therapeutics plc. (5/10/17). "Press Release: Adaptimmune Reports First Quarter 2017 Financial Results". Philadeliphia, PA & Oxford.

	Organisation	Adaptimmune Therapeutics plc (Nasdaq: ADAP)
	Group	Adaptimmune (Group)
	Organisation 2	Matrix Capital Management Company L.P.
	Product	AFP SPEAR™ T-cell therapy
	Product 2	NY-ESO SPEAR® T-cell therapy
	Index term	Adaptimmune–Matrix Capital Management: investment, 201704 direct offering $42m of 7m ADSs at $6/ADS
	Person	Noble, James (Adaptimmune CEO before MediGene 200609–200809 before Avidex)
	Person 2	Tayton-Martin, Helen (Adaptimmune 201703– CBO before COO + Co-Founder before Avidex/Medigene)

Original document
accessed by [iito] on 2017-05-25

Record changed: 2017-05-28

More documents for Adaptimmune (Group)

[1] Adaptimmune Therapeutics plc. (9/5/18). "Press Release: Adaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary Shares". Philadeliphia, PA & Oxford....
[2] Adaptimmune Therapeutics plc. (8/15/18). "Press Release: Third Dosing Cohort to Be Initiated in MAGE-A4 SPEAR T-cell Basket Study After Favorable Review of Safety from One Billion Cell Dose Cohort". Philadeliphia, PA & Oxford....
[3] Adaptimmune Therapeutics plc. (8/2/18). "Press Release: Adaptimmune Reports Second Quarter 2018 Financial Results and Business Update". Philadeliphia, PA & Oxford....
[4] GlaxoSmithKline plc. (7/24/18). "Press Release: GSK and Adaptimmune Complete Transition of NY-ESO SPEAR T-Cell Therapy Programme to GSK"....
[5] Adaptimmune Therapeutics plc. (4/16/18). "Press Release: Adaptimmune Presents MAGE-A4 and MAGE-A10 Pre-clinical Data at American Association for Cancer Research (AACR) Annual Meeting". Philadeliphia, PA & Oxford....
[6] Adaptimmune Therapeutics plc. (4/12/18). "Press Release: Adaptimmune Announces Changes to Board of Directors". Philadeliphia, PA & Oxford....
[7] Adaptimmune Therapeutics plc. (1/8/18). "Press Release: Adaptimmune Announces Positive Safety Data from Pilot Studies with MAGE-A10 SPEAR T-cells and First Patient to Receive 1 Billion Target Cell Dose". Philadeliphia, PA & Oxford....
[8] Adaptimmune Therapeutics plc. (1/8/18). "Press Release: Adaptimmune Announces Two Manufacturing Achievements on Its Way to Become the First Fully Integrated TCR T-cell Therapy Company". Philadeliphia, PA & Oxford....
[9] Adaptimmune Therapeutics plc. (1/4/18). "Press Release: Paul Stead Joins Adaptimmune as Vice President of Business Development". Philadeliphia, PA & Oxford....
[10] GlaxoSmithKline plc. (10/25/17). "Press Release: GSK Delivers Q3 Sales of £7.8 billion, +4% AER, +2% CER". London....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]